Skip to content
  • Sunday, 26 July 2026
  • 2:49 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • MSD Acquires Terns Pharmaceuticals for $6.7 Billion in Strategic Move to Bolster Oncology Pipeline Ahead of Keytruda Patent Expiry
Pharmaceutical R&D

MSD Acquires Terns Pharmaceuticals for $6.7 Billion in Strategic Move to Bolster Oncology Pipeline Ahead of Keytruda Patent Expiry

Teuku Ryan Mar 25, 2026 0

In a significant development poised to reshape the competitive landscape of cancer therapeutics, global pharmaceutical giant MSD (known as Merck…

Read More
Pharmaceutical R&D

Novartis Acquires Promising Breast Cancer Drug SNV4818 from Synnovation Therapeutics for Up to $3 Billion

Teuku Ryan Mar 20, 2026 0

Novartis has announced a significant strategic move to bolster its oncology pipeline with the acquisition of SNV4818, an investigational oral…

Read More

Posts pagination

1 2 3
Empowering Small Businesses: Building an Enterprise-Grade Data Stack with Five Essential Docker ContainersFrom list price to net price: How finance leaders decode real drug costsScientists Replicate Human Bone Marrow Complexities in Groundbreaking Lab-Grown ModelLight’s Hidden Hand: Osaka University Researchers Uncover Novel Mechanism Governing Plant Growth and Structural Integrity
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ